Patent: 10,793,911
✉ Email this page to a colleague
Summary for Patent: 10,793,911
| Title: | Host DNA as a biomarker of Crohn\'s disease |
| Abstract: | The invention relates to methods of analysing a sample from a subject having or suspected of having Crohn\'s disease for the abundance of the subject\'s nucleic acid (e.g., DNA) in the sample. The invention also relates to methods for measuring abundance of nucleic acid (e.g., DNA) in stool from a human subject having or suspected of having Crohn\'s Disease (CD). In various embodiments, an in vitro method includes analysing the relative abundance of the host (human) DNA in said sample of stool or nucleic acid extracted or isolated from a stool sample from the host (human); determining the relative abundance of the host (human\'s) DNA in the sample; and associating the abundance of the host (human) DNA with the host (human) providing the stool sample, or the host (human) providing the stool sample from which the nucleic acid was extracted. |
| Inventor(s): | Cervino; Alessandra Cristina L (Paris, FR) |
| Assignee: | ENTEROME (Paris, FR) |
| Application Number: | 15/877,336 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,793,911
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2035-01-30 |
| Janssen Biotech, Inc. | REMICADE | infliximab | For Injection | 103772 | 08/24/1998 | ⤷ Try a Trial | 2035-01-30 |
| Immunex Corporation | ENBREL | etanercept | For Injection | 103795 | 11/02/1998 | ⤷ Try a Trial | 2035-01-30 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
